- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02685553
Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project
March 4, 2017 updated by: Salvatore Paiella, MD, Universita di Verona
Use of Near Infrared Technology as a Guide in Laparoscopic Resection of Pancreatic Lesions: the COLPAN "Colour-and-resect" Project
The purpose of this study is to determine whether the use of Near-Infrared Technology can guide the laparoscopic resection of hypervascular neoplasms of the pancreas.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Verona, Italy, 37134
- University of Verona Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age between 18 and 80
- diagnosis of hypervascular pancreatic neoplasms to be treated with laparoscopic surgery
Exclusion Criteria:
- allergy to indocyanine green or other vital stains, indium, shellfish
- chronic kidney insufficiency
- chronic hepatopathy
- hyperthyroidism, thyroid adenomas
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
Use of NIR
|
Laparoscopic use of NIR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR
Time Frame: within the time of surgery
|
within the time of surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003 Oct;7(5):626-34. doi: 10.1016/j.cbpa.2003.08.007.
- Verbeek FP, van der Vorst JR, Schaafsma BE, Hutteman M, Bonsing BA, van Leeuwen FW, Frangioni JV, van de Velde CJ, Swijnenburg RJ, Vahrmeijer AL. Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light. J Hepatobiliary Pancreat Sci. 2012 Nov;19(6):626-37. doi: 10.1007/s00534-012-0534-6.
- van der Vorst JR, Vahrmeijer AL, Hutteman M, Bosse T, Smit VT, van de Velde CJ, Frangioni JV, Bonsing BA. Near-infrared fluorescence imaging of a solitary fibrous tumor of the pancreas using methylene blue. World J Gastrointest Surg. 2012 Jul 27;4(7):180-4. doi: 10.4240/wjgs.v4.i7.180.
- Winer JH, Choi HS, Gibbs-Strauss SL, Ashitate Y, Colson YL, Frangioni JV. Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light. Ann Surg Oncol. 2010 Apr;17(4):1094-100. doi: 10.1245/s10434-009-0868-8. Epub 2009 Dec 22.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2016
Primary Completion (Actual)
October 1, 2016
Study Completion (Actual)
October 1, 2016
Study Registration Dates
First Submitted
February 14, 2016
First Submitted That Met QC Criteria
February 17, 2016
First Posted (Estimate)
February 18, 2016
Study Record Updates
Last Update Posted (Actual)
March 7, 2017
Last Update Submitted That Met QC Criteria
March 4, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pancreatic Diseases
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Pancreatic Neoplasms
- Neuroendocrine Tumors
Other Study ID Numbers
- COLPAN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Carcinoma
-
NYU Langone HealthNational Cancer Institute (NCI)RecruitingMetastatic Clear Cell Renal Cell CarcinomaUnited States
-
Jinling Hospital, ChinaNot yet recruitingMetastatic Clear Cell Renal Cell CarcinomaChina
-
Sun Yat-sen UniversityActive, not recruitingNon-Clear Cell Renal Cell CarcinomaChina
-
Neomorph, IncRecruitingRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Kidney Cancer Metastatic | ccRCC | RCC | VHL-Associated Renal Cell Carcinoma | VHL-Associated Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma Metastatic | Kidney CancersUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Arcus Biosciences, Inc.RecruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell CarcinomaUnited States, United Kingdom, Spain, Netherlands, France, Japan, Czechia, Poland, Italy, Germany, Romania, Australia, New Zealand, South Korea, Canada
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); United States Department of DefenseRecruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterRecruitingPhase 1 | Clear Cell Carcinoma | Growth FactorUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Sarcomatoid Renal Cell CarcinomaUnited States
Clinical Trials on NIR
-
UConn HealthNational Institute for Biomedical Imaging and Bioengineering (NIBIB)CompletedBreast CancerUnited States
-
Medisim LtdCompletedElevated TemperatureIsrael
-
Università Politecnica delle MarcheRecruitingCholecystitis; GallstoneItaly
-
Glyconics LtdActive, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); University of TexasCompleted
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingGynecologic SurgeryUnited States
-
Duke UniversityUnited States Department of DefenseWithdrawn
-
Medinol Ltd.Completed
-
University of FloridaNational Institute on Aging (NIA); University of ArizonaActive, not recruitingCognitive Aging | Alzheimer Disease, Protection AgainstUnited States